ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
No open-market purchases or sales by ARS Pharmaceuticals, Inc. insiders were filed in the last 90 days; 208 institutions reported holding it in 13F filings for Q2 2026, worth $726.0M in total; Third Point is the only superinvestor holding it.
Key figures
- Market capClose on Nov 9, 2026
- $316.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 208
- 13F valueReported value at the end of Q2 2026
- $726.0M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $84.3M
- −5.5% year over year
- Net income, FY2025
- -$171.3M
- −2,241.8% year over year
- Free cash flow, FY2025
- -$171.2M
- −1,418.5% year over year
- Revenue, Q3 FY2026
- $37.7M
- +16.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $171.3M (203.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 19.8M
- Shares sold short
- Change
- −1.37M
- −6.5% vs. previous
- Days to cover
- 12.56
- At average daily volume
Superinvestors holding SPRY, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding ARS Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Third Point
Daniel Loeb
0.2%
ARS Pharmaceuticals, Inc.'s share of the portfolio
- Shares
- 1,000,000
- Value
- $8.01M
Latest insider trades
See all insider tradesOpen-market purchases and sales by ARS Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 (view filing) | Jun 12 | Same day | Karas EricChief Commercial Officer | SSale | −25.0K | $10.00 | −$250.0K | −67.2%12.2K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 12 | Same day | Fitzpatrick Alexander AChief Legal Officer | SSale | −3.35K | $10.00 | −$33.5K | −3.6%90.9K after | 10b5-1 |
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Chakma JustinChief Business Officer | SSale | −166.4K | $8.87 | −$1.48M | −100.0%0 after | 2 lots |
| Nov 14, 2025 (view filing) | Nov 13 | 1 day | Dorsey BrianChief Operating Officer | SSale | −21.8K | $8.71 | −$190.1K | −66.9%10.8K after | |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Lowenthal Richard EPRESIDENT AND CEO | SSale | −50.0K | $14.49 | −$724.5K | −4.0%1.20M after | 10b5-1 |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Scott Kathleen D.Chief Financial Officer | SSale | −12.5K | $15.00 | −$187.5K | −55.5%10.0K after | 10b5-1 |
| Aug 21, 2025 (view filing) | Aug 19-20 | 2 days | Tanimoto SarinaCHIEF MEDICAL OFFICER | SSale | −50.0K | $14.08 | −$703.8K | −3.9%1.25M after | 2 lots10b5-1 |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Karas EricChief Commercial Officer | SSale | −15.0K | $16.99 | −$254.8K | −59.3%10.3K after | 10b5-1 |
| Jul 1, 2025 (view filing)4:42 PM ET | Jun 27 | 4 days | Deerfield Management Company, L.P. and 5 others10% Owner | SSaleClass A Common Stock | −740.1K | $18.46 | −$13.7M | −13.2%4.89M after | 2 lots |
| Jun 20, 2025 (view filing) | Jun 18 | 2 days | Karas EricChief Commercial Officer | SSale | −15.0K | $16.00 | −$240.0K | −66.1%7.70K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 208 holdersThe largest institutional positions in ARS Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 10,860,977 | $87.0M | 0.76% | 00.0% | Unchanged |
| Rubric Capital Management LP | 8,540,861 | $68.4M | 0.63% | +540,861+6.8% | Added |
| OrbiMed Advisors LLC | 8,288,510 | $66.4M | 1.26% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 7,503,812 | $60.1M | 0.63% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,311,319 | $42.5M | 0.00% | +299,065+6.0% | Added |
| Tyro Capital Management LLC | 4,459,337 | $35.7M | 8.01% | +1,490,738+50.2% | Added |
| Standard Life Aberdeen plc | 4,170,629 | $33.4M | 0.05% | +57,012+1.4% | Added |
| Sr One Capital Management, LP | 4,012,903 | $32.1M | 3.09% | 00.0% | Unchanged |
| State Street Corp | 3,730,623 | $29.9M | 0.00% | +85,657+2.4% | Added |
| Capital World Investors | 2,754,931 | $22.1M | 0.00% | +2,754,931 | New |
Holders of 5% or more of SPRY
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of ARS Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 11.10%10.9M shares | – | Feb 16, 20216 filings | Oct 1, 2025 | SEC |
| Rubric Capital Management LP | 13G/A | 8.06%8.00M shares | +1.79 ppfrom 6.27% | Feb 13, 20262 filings | May 15, 2026 | SEC |
| Flynn James E | 13D/A | 7.75%7.61M shares | −1.04 ppfrom 8.79% | Nov 18, 20225 filings | Aug 1, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.30%5.22M shares | +0.32 ppfrom 4.98% | Jan 21, 20263 filings | Jul 27, 2026 | SEC |